🇺🇸 FDA
Pipeline program

Linvoseltamab

R7945-ONC-22110

Phase 2 small_molecule active

Quick answer

Linvoseltamab for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials